STI Stock Trade Intelligence
PTX

PRESCIENT THERAPEUTICS LIMITED

Health Care · ASX:PTX
$0.0650
▲ +1.56%
Market cap
$74M
Turnover
$19,651
Last price
$0.0650
Day change
+1.56%
Announcements
14
Range, past year
Open 0.043 · Low 0.040 · Now 0.065 · High 0.125
Open PTX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

PTX momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-10-13.
Momentum quality
27/100
Wyckoff phase
Accumulation17d
Trend stage
Neutral
1 Day
+1.6%
1 Week
+0.0%
1 Month
+0.0%
1 Year
+51.2%
RSI
43
Avg daily range
4.4%

PRESCIENT THERAPEUTICS LIMITED scores 27 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 17 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently matching and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -31.9%
  • Thin liquidity
  • Risk rating: High
  • Composite downside risk elevated
PTX appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

PTX announcements

Recent price-sensitive releases.
  • 2026-10-13 September 2026 Quarterly Update and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Web Cast | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-09-23 PTX Successfully Completes $6m Raise Via SPP and Placement Placement | Trading Halt Lifted | Security Purchase Plan
  • 2026-09-21 Trading Halt Trading Halt
  • 2026-09-15 Prescient Therapeutics - Extension of Share Purchase Plan Web Cast | Security Purchase Plan
  • 2026-09-08 Prescient Therapeutics - Extension of Share Purchase Plan Web Cast | Security Purchase Plan
  • 2026-09-02 PTX-100 CTCL Phase 2a study reaches review milestone Web Cast | Progress Report
  • 2026-08-26 Prescient Therapeutics Opens SPP to Raise $7m Today Web Cast | Letter to Shareholders | Security Purchase Plan
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.